© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
Good News for Patients with Strep
The Amoxicillin PULSYS Phase III Trialachieved its clinical goals in the treatmentof adults and adolescents withpharyngitis/tonsillitis due to Group Astreptococcal infections (strep throat).Advancis Pharmaceutical Corp enrolled620 adults and adolescents in a randomized,double-blind, multicenter, noninferioritytrial in November 2005. Researcherscompared the once-daily, 775-mg tablet of Amoxicillin PULSYS for 10days with 250 mg of penicillin VK 4 timesa day for 10 days. The primary desiredend point of the trial was bacterial eradicationat the "test-of-cure" visit forpatients who had completed the protocol,measured by throat cultures beforeand after treatment. Bacterial eradicationat the posttherapy test-of-cure visitamong the patients who had completedthe protocol was 85% in the AmoxicillinPULSYS group and 83.4% with penicillin.Stan L. Block, MD, an investigator in thestudy and a professor of clinical pediatricsnoted, "The outcomes wereachieved through a single-daily-doseadministration, a significant factor withthe potential to positively impact patientcompliance."
Ms. Farley is a freelance medicalwriter based in Wakefield, RI.